On March 16, 2022 Oligon Inc., an emerging biotechnology company developing a novel class of multimodal RNA therapeutics for the treatment of cancer and other diseases, reported that three abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 (Press release, Oligon, MAR 16, 2022, View Source [SID1234610199]). The AACR (Free AACR Whitepaper) 2022 Conference will be held in New Orleans, LA from April 8-13, 2022.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Spyro Mousses, CEO of Oligon, further commented, "Our SeekR RNA therapeutic platform is the best in class for single agent multitargeting, and we are thrilled at the opportunity to share our latest results with the cancer research community. Specifically, we will be publicly disclosing for the first time novel SeekR details and proprietary component compositions. Additionally, we will be presenting pre-clinical results for our lead cancer-targeting and IO-targeting candidates. In addition to our scientific presentations, our business development team and I will also be at the conference and available to meet with pharma partners who are interested in exploring strategic collaborations."
Details of the abstracts are as follows:
Title: Development of novel anticancer RNA therapeutics with dual-targeting siRNA that silences ubiquitin family members
Abstract Number: 3977
Title: Development of multi-targeting immunomodulatory SeekR RNA therapeutics to overcome resistance to PD-1 blockade
Abstract Number: 4045
Title: Leveraging single-cell RNA sequencing data to design multi-targeting SeekR RNA therapeutics
Abstract Number: 5078